

#### **Ralfinamide:**

- An innovative therapeutic oral agent for neuropathic pain with potential in inflammatory pain
- Small molecule, part of a new chemical class with linear kinetics and excellent “drugability”
- Blocks ion channel subtypes implicated in pain transmission
- Long-lasting anti-allodynic and anti-hyperalgesic effects in models of neuropathic pain
- No development of tolerance on chronic dosing
- Clear evidence of efficacy in a phase II placebo controlled trial in patients with neuropathic pain demonstrated that ralfinamide may provide a unique therapeutic benefit for patients with NLBP. Phase IIb/III trials in NLBP are expected to commence next

#### *HF0220:*

- A first-in-class therapeutic with powerful cytoprotective and regenerative effects
- An ongoing phase II safety and tolerability study exploring biological markers in patients with Alzheimer’s disease
- A phase II study in rheumatoid arthritis to be initiated next

#### *HF0420:*

- A low molecular weight oligosaccharide in phase I for prevention of anti-cancer therapy induced neuropathy

#### *HF0299:*

- A naturally occurring human steroid in phase I with potential in the treatment of neuropathic pain

#### *NW 3509:*

- Novel treatment for mania and other CNS diseases, in pre-clinical stage

#### **Drug Discovery**

Newron’s pre-clinical and clinical pipeline is supported by a portfolio of early-stage proprietary compounds.

#### **Strategy**

Newron’s goal is to become a fully integrated biopharmaceutical company focused on the discovery, development and commercialisation of drugs for the treatment of CNS-related diseases, inflammation and pain, originated from its internal discovery effort and from licensing and acquisitions.

#### **Collaborations**

In 2006, Newron signed an agreement with Serono (now Merck Serono) giving them exclusive worldwide rights to develop, manufacture and commercialise safinamide in PD, Alzheimer’s disease (AD) and other therapeutic applications. The deal is worth up to \$200 million in upfront and milestone payments, plus royalties to Newron, and gives the company the option to co-promote safinamide in Italy and Spain.

#### **Management**


Newron’s senior management has an average of 25 years of experience in developing and bringing to the market drugs for CNS diseases such as AD, PD, epilepsy, sleep disorders etc. In addition, senior executives from the pharmaceutical and life science venture capital industry serve on the Board, chaired by Rolf Stahel.

- Luca Benatti, Chief Executive Officer, Director, Founder
- Stefan Weber, Chief Financial Officer
- Ravi Anand, Chief Medical Officer
- Carlos De Sousa, Chief Business Officer
- Stefano Rossetti, VP Clinical Development & Regulatory Affairs
- Marco Caremi, VP Strategic Marketing and Head of Legal Affairs
- Patricia Salvati, VP Preclinical R&D, Founder

#### **Funding**

From inception in 1999, Newron raised a total of €62.2m of equity from a group of international life science venture capital investors including 3i, Atlas Venture, Apax, HBM BioVentures, HBM BioCapital and TVM Capital.

In December 2006, Newron was floated on the SWX Swiss Exchange, raising €74.3m.



#### **Contacts**

For further information on Newron and its products, please visit [www.newron.com](http://www.newron.com) or contact:

#### **Media**

##### *Italy*

Luca Benatti - CEO  
Phone: +39 02 6103 4 626  
E-Mail: [pr@newron.com](mailto:pr@newron.com)

##### *UK/Global media*

Julia Phillips  
Financial Dynamics  
Phone: +44 (0) 20 7269 7187

##### *Switzerland*

Martin Meier-Pfister  
The Investor Relations Firm AG  
Phone: +41 43 244 81 40

#### **Investors and analysts**

Stefan Weber – CFO  
Phone: +39 02 6103 46 30  
E-Mail: [ir@newron.com](mailto:ir@newron.com)

